Liver Transplantation
Conditions
Brief summary
The purpose of this study is to investigate and validate the maximum tolerated dose (MTD) or maximum available dose (MFD), safety and efficacy on patients with hepatocellular carcinoma beyond Milan criteria who undergo liver transplantation.
Detailed description
ILC-IIT-07 is open-label, phase 1/2 clinical trial to confirm safety on patients with hepatocellular carcinoma beyond Milan criteria who undergo liver transplantation. For primary outcome, maximum feasible dose (MFD) or maximum tolerated dose (MTD) will be evaluated. For secondary outcome, Time to Recurrence(TTR), Recurrence-Free Survival(RFS), Overall Survival(OS) will be evaluated.
Interventions
BIOLOGICALImmuncell-LC
Activated T lymphocyte
Sponsors
GC Cell Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Liver cancer patients undergoing liver transplantation with hepatocellular carcinoma exceeding the Milan criteria
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who are more than 20 and less than 80 years old. * Patients whose expected life expectancy is at least 16 weeks (4 months). * Patients who receive liver transplants exceeding the Milan Criteria. * ECOG Performance Status (ECOG-PS) score is 0-2. * Patients who satisfy the following conditions of the blood test and kidney, liver function test. Absolute neutrophil count \> 500x10\^6L Hemoglobin ≥ 7.5 g/dL Platelet count \> 20,000/㎣ Total bilirubin \< 15mg/㎗ •Patients who have agreed to participate in the study voluntarily by signing on informed consent form.
Exclusion criteria
* Patients who have received in vitro radiation therapy, systemic chemotherapy within 4 weeks based on sign date of Informed consent form. * Patients who undergo ABO incompatible Liver Transplantation. * Patients who had previously administered cell therapy. * Patients who are confirmed with Acquired Immune Deficiency Syndrome (AIDS). * Patients who are currently receiving dialysis. * Patients who participated in another clinical trial and received treatment in 4 weeks or have a plan for administration of another clinical trial treatment since Informed consent form sign date. * Patients who have uncontrollable or serious disease. * Patients who are unable to use appropriate methods of contraception during the study period. * Patient whose tumor has not been removed or liver metastasis is confirmed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| maximum tolerated dose (MTD) or maximum feasible dose (MFD) | Every visit from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject | The observation of maximum tolerated dose (MTD) or maximum feasible dose (MFD) evaluation(1X10\^7cell, 5X10\^7cell, 10X10\^7cells) of immuncell-LC on hepatocellular carcinoma patients who undergo liver transplantation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Recurrence | Every visit from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject | Time to Recurrence is defined as the recurring time of the cancer. |
| Recurrence-Free Survival | Every visit from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject | Recurrence-Free Survival is defined as the recurring time of the cancer or death. |
| Overall Survival | Every visit from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject | Overall Survival is defined as the time of death from administraion of investigational product. |
Countries
South Korea
Outcome results
None listed